Activity Title: ExpertPerspectives: Recent Advances and Optimal Management of Erythropoietic Protoporphyria and X-linked Protoporphyria

TARGET AUDIENCE:
This activity is intended for a national audience of hematologists, hepatologists, gastroenterologists, medical geneticists, dermatologists, advanced care practitioners, primary care physicians, and other healthcare providers who may be involved in diagnosis and treatment of patients with EPP and XLP.
PROGRAM OVERVIEW:
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are cutaneous porphyria responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances, including new classes of medications, continue to be made. In this educational activity, Karl Anderson, MD, discusses preventive and therapeutic options for patients with EPP and XLP, as well as the safety and efficacy of emerging treatments.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
• Employ preventive and therapeutic options for patients diagnosed with EPP and XLP that best fit the need of each patient
• Describe the safety and efficacy of emerging treatments for patients with EPP and XLP